{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-24-000061","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.234905+00:00","generated_at":"2026-05-30T05:24:15.305008+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entrada Q3 net loss $14.0M; advancing DMD franchise with regulatory filings on track","bullets":["Net loss $14.0M in Q3 2024 (vs $35.5M net income in Q3 2023); revenue down to $19.6M from $43.7M.","Cash $449.3M as of Sep 30, 2024, up from $352.0M at end of 2023; funded by $100M offering and $75M milestone.","R&D expenses $31.3M (vs $22.2M) driven by DMD candidates; G&A $10.0M (vs $7.5M).","On track to submit global regulatory filings for Phase 2 trials of ENTR-601-44 and ENTR-601-45 in Q4 2024.","Vertex completed SAD and initiated MAD for VX-670 in DM1; Sethuraman promoted to President of R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-24-000061","json":"https://secwatch.observer/filing/0001689375-24-000061.json","markdown":"https://secwatch.observer/filing/0001689375-24-000061.md","text":"https://secwatch.observer/filing/0001689375-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000061/0001689375-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000061/trda-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:24:15.305008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}